USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: Alexza Molecular Delivery Corporation
Address: Alexza Molecular Delivery Corporation
1001 E Meadow Cir
Palo Alto, CA 94303
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: (650) 687-3902

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,590,852.00 8
SBIR Phase II $5,925,177.00 4

Award List:

NOVEL INHALATION SYSTEM FOR DELIVERING VAPOR-STATE DRUGS

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Daniel Mufson
Award Amount: $99,510.00
Abstract:
Delta-9-tetrahydrocannibinol (THC) is approved for AIDS-related anorexia, chemotherapy-related nausea and vomiting, and clinical evidence supports efficacy of THC in pain, even suggesting an opioid sparing strategy with equivalent analgesia. Current THC formulations have significant disadvantages,… More

TREATMENT OF MIGRAINE ATTACKS BY DRUG AEROSOL INHALATION

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Joshua D. Rabinowitz
Award Amount: $270,089.00
Abstract:
DESCRIPTION (provided by applicant): Migraine is a serious condition affecting millions of Americans. Patients with migraine strongly desire more rapid headache relief than current medications provide. A promising approach to expediting pain relief is delivery of existing drugs to the systemic… More

Novel Inhalation Device for Delivering Vapor-State Drugs

Award Year / Program / Phase: 2003 / SBIR / Phase II
Agency: HHS
Principal Investigator: Joshua D. Rabinowitz
Award Amount: $1,425,721.00
Abstract:
DESCRIPTION (provided by applicant): Poor appetite is one of the subjective symptoms that cancer patients find most frustrating, and resulting cachexia is a common cause of death from cancer. In addition, nausea is a frequent side effect of cancer treatment. Oral delivery of the cannabinoid agonist… More

Migraine Headache Treatment by Drug Aerosol Inhalation

Award Year / Program / Phase: 2003 / SBIR / Phase II
Agency: HHS
Principal Investigator: Joshua D. Rabinowitz
Award Amount: $1,386,303.00
Abstract:
DESCRIPTION (provided by applicant): Migraine is a serious condition affecting millions of Americans. Patients with migraine strongly desire more rapid headache relief than current medications provide. A promising approach to expediting pain relief is delivery of existing drugs to the systemic… More

Inhaled dopamine agonist for late stage Parkinsonism

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Joshua D. Rabinowitz
Award Amount: $281,289.00
Abstract:
DESCRIPTION (provided by applicant): Later stages of Parkinson's disease are often characterized by motor fluctuations that include unpredictable and severely disabling periods of complete immobility ("off" periods). The most effective pharmacological treatments for "off' periods are dopamine… More

Inhaled dopamine agonists for late stage Parkinsonism

Award Year / Program / Phase: 2004 / SBIR / Phase II
Agency: HHS
Principal Investigator: Patrik Munzar
Award Amount: $1,619,223.00
Abstract:
DESCRIPTION (provided by applicant): Many patients in the later stages of Parkinson's disease experience periods of acute immobility ("off' periods) that substantially decrease their quality of life. The most effective pharmacological treatments for these acute "off' periods are dopamine agonist… More

Novel Inhalation System for Delivery of Nicotine

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Janet A. Tamada
Award Amount: $145,949.00
Abstract:
DESCRIPTION (provided by applicant): Despite the severe health consequences of smoking and the desire of most smokers to quit, tens of millions of Americans continue to smoke. This in part reflects the poor efficacy of existing smoking cessation therapies, which result in sustained abstinence in a… More

Inhaled Loop Diuretics for Congestive Heart Failure

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Daniel J. Myers
Award Amount: $199,709.00
Abstract:
DESCRIPTION (provided by applicant): Congestive heart failure (CHF) is a complex syndrome characterized by multiple symptoms including fluid retention and shortness of breath (dyspnea). Although these symptoms are currently generally treated by oral loop diuretics, intravenous (IV) delivery of loop… More

Treatment of Agitation by drug Aerosol Inhalation

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Patrik Munzar
Award Amount: $196,998.00
Abstract:
DESCRIPTION (provided by applicant): Acute agitation is a serious and common complication of a variety of major psychiatric disorders, including dementia, schizophrenia and mania. In addition, it is one of the most detrimental factors in the continued stigmatization of mental illness. The current… More

Treatment of Pain by Drug Aerosol Inhalation

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: William W. Shen
Award Amount: $196,275.00
Abstract:
DESCRIPTION (provided by applicant): Breakthrough pain is a feared symptom afflicting the majority of cancer patients at some point in their illness. It is characterized by rapid onset, with pain intensity reaching excruciating level within several minutes, and brief duration (median duration… More

Asthma Treatment with a Novel Drug Aerosol Generator

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: William W. Shen
Award Amount: $201,033.00
Abstract:
DESCRIPTION (provided by applicant): Asthma is a chronic disease characterized by inflammation of the airways and lung, causing attacks characterized by wheezing and shortness of breath. Around 5% of the population in the United States suffers from asthma, with the prevalence of this disease… More

Treatment of Pain by Drug Aerosol Inhalation

Award Year / Program / Phase: 2005 / SBIR / Phase II
Agency: HHS
Principal Investigator: William W. Shen
Award Amount: $1,493,930.00
Abstract:
DESCRIPTION (provided by applicant): Breakthrough pain is a feared symptom afflicting the majority of cancer patients at some point in their illness. It is characterized by rapid onset, with pain intensity reaching excruciating level within several minutes, and brief duration (median duration… More